

**Johnson & Johnson Innovative Medicine**  
**Selected Novel Therapies - Recent Approvals/Potential Filings\***  
**(2023-2030 Key Filings, As Outlined at 2023 Enterprise Business Review)**

Selective Highlights as of January 21, 2026

**Assets with \$5B+ PYS Potential**

**Oncology**  
**CD20-based CAR-T**  
Lymphoma

✓ **RYBREVANT / LAZCLUZE**  
Non Small Cell Lung Cancer

✓ **TALVEY (talquetamab)**  
Relapsed Refractory Multiple myeloma

✓ **TARIS Platform \***  
Bladder Cancer

**Immunology**  
 **icotrokinra**  
Autoimmune Diseases

**Neuroscience**  
 **IMAAVY (nipocalimab)**  
Autoantibody Diseases

**Select Other Areas**  
**Milvexian**  
Thrombosis

**Assets with \$1 – 5B PYS Potential**

**Oncology**  
**bleximenib**  
Hematologic Malignancies

**JNJ-5322 (BCMA/GPRC5D/CD3)**  
Hematologic Malignancies

**JNJ-6420 225Ac KLK2**  
Prostate Cancer

**JNJ-8343 KLK2 / CD3**  
Prostate Cancer

**JNJ-8543 (CD79/CD20/CD3)**  
Hematologic Malignancies

✓ **AKEEGA (niraparib/abiraterone)**  
Metastatic castration-resistant prostate  
cancer (mCRPC)

**Immunology**  
**JNJ-4804 Co-antibody Therapy**  
Inflammatory Bowel Disease

**Neuroscience**  
**JNJ-1887 sCD59**  
Geographic Atrophy

**RPGR Gene Therapy**  
Retinitis Pigmentosa

**selexreant**  
Adjunctive treatment for major depressive  
disorder with insomnia symptoms

Submitted in US or EU  
 Approved in US or EU

PYS refers to peak year non-risk adjusted operational sales, including partner sales. Filings/approvals assumed to be in the US and EU unless otherwise noted. This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

Niraparib licensed from Tesaro; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab, Talquetamab); Lazertinib licensed from Yuhuan Corporation; AAV-RPGR licensed from UCL Business Plc; JNJ-1887 acquired from Hemera Biosciences; Milvexian co-developed with Bristol Myers Squibb; (CAR) T-cell therapies [JNJ-90014496 and JNJ-90009530] AbelZeta collaboration and license agreement; JNJ-2113 licensed from and co-developing with Protagonist Therapeutics, Inc.; NBTXR3: Nanobiotix

\*Total TARIS platform is expected to be \$5B+ in non risk adjusted peak year sales. This includes both TAR-200 and TAR-210; approval above is specific to only TAR-200.